Lixisenatide

(Adlyxin)

Lixisenatide

Drug updated on 11/13/2023

Dosage FormInjection (subcutaneous; 50 mcg/mL, 100 mcg/mL)
Drug ClassGlucagon-like peptide-1 (GLP-1) receptor agonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Product Monograph / Prescribing Information

Document TitleYearSource
Adlyxin (lixisenatide) Prescribing Information.2022Sanofi-Aventis U.S. LLC, Bridgewater, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Current Utilization Patterns of GlucagonLike Peptide-1 Receptor Agonists.2022CADTH
GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2022Endocrine Society
Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis.2021Diabetes Therapy
Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.2021Prime Care Diabetes
Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.2021Journal of Cardiovascular Pharmacology
Gastrointestinal adverse events with insulin glargine/ lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: a network meta-analysis. 2020Diabetes, Obesity and Metabolism
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.2020Diabetes, Obesity and Metabolism
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.2020Nutrition, Metabolism and Cardiovascular Diseases
Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies2020International Journal of Clinical Practice
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.2019Lancet Diabetes Endocrinology
An evaluation of the clinical therapeutic effect of lixisenatide in type 2 diabetes patients: a systematic literature review.2018Current Diabetes Reviews
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.2018Lancet Diabetes Endocrinology
PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.2018Medicine
Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.2018Current Diabetes Reviews

Clinical Practice Guidelines